Home » Profilo » CV Stefano Pallanti

CURRICULUM VITAE

STEFANO PALLANTI, M.D. PhD

EDUCATION

Medical Doctorate Degree (M.D.) and European Medical License, 6-year course, final dissertation thesis “Life events and Depression”

University of Florence, School of Medicine, Florence, Italy

November 1987

Residency In Psychiatry, 4-year course, final dissertation thesis “Life Events and Schizophrenia”

University of Florence, School of Medicine, Florence, Italy

June 1993
Ph.D in Neurophysiopathology, 4-year course, final dissertation thesis “Contingent Negative Variation in Normal Elderly Population “ University of Florence, School of Medicine, Florence, Italy

May 2013
Certificate of Deep TMS Operation, completed by Brainsway Inc., Israel

MEDICAL LICENSES

Italian Licence to Practice, Registration at the Provincial Association of Doctor- Surgeons and Dentists in Florence, Italy: Licenced on 30 November 1987, Registered on 23 January 1984, Licence number 7745

General Medical Council (UK) Registration: 18 June 2012, Registration n°7125393

Schweizerische Eidgenossenschaft (Swiss Confederation) Registration: 7 November
2012, Registration n° GNL7601000979667

Medical Board of California, USA: 13 November 2013 – 13 November 2014, Registration n°F5799, NPI n° 19322939038, DEA Registration number: FP4286628 (2113 Permit)

PROFESSIONAL APPOINTMENTS

Present Employment

January 1989 – Present

Founder, Owner, CEO, Administrator, Strategic and Scientific Director, Istituto di Neuroscienze, Via A. Lamarmora 24, Firenze, Italy, A private institution for research, diagnosis, rTMS and tDCS therapy in Psychiatry, Neurology and Clinical Psychology. Accredited by the University of Florence for Post-Graduate Internship.

November 2001 – Present

Tenured Professor of Psychiatry University of Florence, School of
Medicine, Florence, Italy

January 2004 – Present

Founder, Director and Administrator, Clinical Neurosciences ONLUS, Via
Dè Fossi 12, Firenze, Italy, A non-profit organization that organizes scientific CME courses in collaboration with the University of Florence (Italy)

Academic Appointments

November 2000 – November 2010

Scientific Secretary and Coordinator, Tuscany School of Psychiatry (Three
Tuscan Universities’ Consortium: University of Florence, Pisa and Siena) November 2004 – November 2007
Board Member and Coordinator, International Affairs Office of the
University of Florence

November 2004 – Present

Member of Board of Directors, International Master in Affective
Neuroscience, University of Maastricht, The Netherlands and University of Florence, Italy

November 2004 – November 2005

Visiting Associate Professor in Overseas Studies, Stanford Program in
Florence, School of Humanities and Sciences, Stanford University

November 2004 – November 2005

Professor in Emergency Psychiatry, Emergency Medicine Post Doctorate Master course, Harvard School of Medicine, Massachusetts, U.S. and University of Florence, Florence, Italy

November 2006 – November 2007

Director and Organizer, Medical School Course of Psychiatry in English,
University of Florence, Italy

January 2007 – January 2008

Director, Strategic Center of Excellence of Psychiatry, Mount Sinai School of Medicine, New York, USA

November 2008 – Present

Member of Board of Directors, Dottorato Toscano di Neuroscienze,
University of Florence, School of Medicine, Florence, Italy

November 2008 – November 2010

Director of Master in Mindfulness (“Meditation and Mindfulness: Neurosciences and Clinical applications in Health Care”) University of Florence

November 2010 – November 2013

Director of the Graduate Course on Health Education, University of
Florence, School of Medicine, Florence, Italy

November 2010 – November 2017

Chair of Education and Director of the Residency Program of Psychiatry,
University of Florence, School of Medicine, Florence, Italy

November 2012 – Present

Italian National Scientific Qualification as a full professor

November 2013 – November 2014

Professor of Psychiatry and Associate Physician, Early Diagnosis and Preventive Treatment Clinic, Associate physician Psychosomatic Unit, Responsible for the Neuromodulation Program, UC Davis, CA, USA

Clinical Activities

January 2000 – Present

Dirigente Medico 1st level (Medical Director), Psychiatric Clinic, Azienda Ospedaliero Universitaria Careggi (University of Florence Hospital), Department of Neurosciences

January 2000 – Present

Director of the OCD Spectrum Disorders programme, Psychiatric Clinic, Azienda Ospedaliero Universitaria Careggi, University of Florence Hospital, Department of Neuroscience

January 2009 – January 2014

Director of Psychosomatic and Liaison psychiatry, Azienda Ospedaliera
Universitaria Careggi, University of Florence, Florence, Italy

November 2013 – November 2014

Clinical Practice, Sacramento EDAPT and EDAP programs (Early Diagnosis and Preventing Treatment of Psychosis Illness), Liaison Psychiatry Consultant, UC Davis Medical Hospital, CA, USA

Professional Memberships

September 2011 – Present

Member of the ECNP Obsessive Compulsive and Related Disorders
Network

October 2013 – Present

Fellow, European College of Neuropsychopharmacology

January 2013 – Present

Member of the New York Psychiatric Society, NY, USA

May 2014 – Present

International Fellow, American Psychiatric Association (APA)

May 2017 – Present

Member of the PANDAS Physicians Network

Service to Professional Organizations

May 1994 – May 2004

International Advisory Board member, APA for DSM V and DSM 5.0 TR

January 1999 – January 2004

Member of the Steering Committee, International OCD Consortium

November 2002 – Present

Member of Board of Directors, International Master in Affective
Neuroscience, Universities of Maastricht and Florence

January 2004 – Present

Board member, International College of Obsessive Compulsive
Spectrum Disorders (ICOCS), UK

September 2004 – Present

Scientific Advisory Panel Member for Anxiety and Anxiolytics session,
European College of Neuropsychopharmacology (ECNP)

May 2005 – May 2008

Member of International Advisory Board, American Psychiatric
Association (APA) for DSM 5.0 (Chair D.J. Kupfer)

May 2005 – May 2007

Member of the OCD spectrum workgroup Impulse Control Disorders Taskforce and International Advisory Board, American Psychiatric Association (APA) for DSM 5.0 (Chair D.J. Kupfer)

June 2009 – Present

Member of the Advisory Council, icare4autism (International Center for
Autism Research and Education), New York, USA

September 2011 – December 2014

Member of the European College of Neuropsychopharmacology
Educational Committee

May 2013 – May 2017

Member of the Board of Directors, Clinical TMS Society, Greenwich, CT

October 2014 – Present

World Health Organization expert in Anxiety

October 2015 – Present

Member of the Board, (anxiety section) World Psychiatric Association

Sepbember 2016 – Present

Executive Committee Member, European College of
Neuropsychopharmacology

Professional Honors and Awards

October 2004 ECNP poster-travel award

February 2005 Società Italiana di Psicopatologia (SOPSI) poster research award

May 2007 CNS Spectrum 2007 Breakthrough Paper Award

TEACHING

University of Florence, Italy

November 1993 – Present

Psychopathology Course (Course Director and Lecturer) November 1993-Present
Psychopathology in the Residency Programme (Course Director and
Lecturer) November 2000-Present
Undergraduate Psychiatry Course (Course Director and Lecturer) November 2001-Present
Medical Thesis Advising

November 2010-Present

Post-Graduate Psychiatry Course (Course Director and Lecturer) November 2010-Present
Psychopharmacology Course Course (Course Director and Lecturer) November 2016 – June 2017

Neurocircuitry Research Domain Criteria and Precision Psychiatry
Course (Course Director and Lecturer)

University of Maastricht and University of Florence,

November 2004 – Present

International Master Degree in Affective Neuroscience (joint program)
– course design, material development, lectures, and thesis advising

Continuing Medical Education (CME) European Accreditation Council for CME January 2009 – December 2013

Managing Anxiety in Practice CME Course design, course material development (Slides, Booklet and CD-ROM) and lectures. Total of 6 courses held in Berlin (Germany), London (UK), Athens (Greece), Rome (Italy), Munich (Germany) and Paris (France)

SCHOLARSHIP

Peer-Reviewed Original Research Publications (160 total)

1. Faravelli C, Sacchetti E, Ambonetti A, Conte G, Pallanti S, Vita A. Recent life events and affective disorder revisited. British Journal of Psychiatry. 1986
Mar;148:288-95.

2. Faravelli C, Ambonetti A, Pallanti S, Pazzagli A. Depressive relapses and incomplete recovery from index episode. American Journal of Psychiatry. 1986
Jul;143(7):888-91.

3. Faravelli C, Pallanti S. Clomipramine by different routes of administration: short- and long-term efficacy and predictors of clinical outcome. Psychopharmacol Bull. 1987;23(3):459-63.

4. Faravelli C, Pallanti S, Frassine R, Albanesi G, Guerrini Degl’Innocenti B.
Panic attacks with and without agoraphobia: a comparison. Psychopathology.
1988;21(1):51-6.

5. Faravelli C, Pallanti S, Strik WK. [Stress load and schizophrenic disorder].
Nervenarzt. 1988 Apr;59(4):237-9. German.

6. Faravelli C, Pallanti S. Recent life events and panic disorder. American
Journal of Psychiatry. 1989 May;146(5):622-6.

7. Smeraldi E, Orsini A, Gasperini M, Sciuto G, Battaglia M, Cassano GB, Perugi G, Faravelli C, Pallanti S, Bressa G. Familial analysis of panic disorder and agoraphobia. Journal of Affective Disorders, 1989, vol.17, p.1-8. ISSN: 0165-0327.

8. Faravelli C, Guerrini Degl’Innocenti B, Aiazzi L, Incerpi G, Pallanti S.
Epidemiology of mood disorders: a community survey in Florence. Journal of
Affective Disorders. 1990 Oct;20(2):135-41.

9. Faravelli C, Panichi C, Pallanti S, Paterniti S, Grecu LM, Rivelli S.
Perception of early parenting in panic and agoraphobia. Acta Psychiatrica
Scandinavica. 1991 Jul;84(1):6-8.

10. Faravelli C, Pallanti S, Biondi F, Paterniti S, Scarpato MA. Onset of panic disorder. American Journal of Psychiatry. 1992 Jun;149(6):827-8.

11. Pallanti S, Mazzi D. MDMA (Ecstasy) precipitation of panic disorder.
Biological Psychiatry. 1992 Jul 1;32(1):91-5.

12. Zaccara G, Gangemi PF, Muscas GC, Paganini M, Pallanti S, Parigi A, Messori A, Arnetoli G. Smooth-pursuit eye movements: alterations in Alzheimer’s disease. Journal of the Neurological Science. 1992 Oct;112(1-2):81-9.

13. M.Weissman, L.Bobins, J.Escobar, R.Bland, G.Canino, H.Wittchen, C.Faravelli, S.Pallanti, J.Lepine, P.Pariente, E.Karam, J.Wells, H.Hwu, G.Klerman, P.Lavori, W.Maier (1992). The changing rate of depression. JAMA, vol. 268, p.
3098-3105, ISSN: 0098-7484.

14. Pallanti S., Pavia R.S. A demencia emu ma prospectiva psico (pato) lògica. [Dementia in a psycho(patho)logical perspective] Jornal Brasiliero de Psiquiatria [Brazilian Journal of Psychiatry] 41 (9), 447-50. Ott. 1992.

15. Faravelli C., Pallanti S., Biondi F., Paterniti S., Scarpato M.A. Assessment of onset of panic disorder in relatrion to onset of agoraphobia-replay. American Journal of Psychiatry 150 (9), 1437-1437. 1993-09-01.

16. Mortilla M, Amaducci L, Bruni A, Montesi MP, Trubnikov A, De Cataldo S, Pallanti S, Pazzagli A, Grecu L, Servi P, et al. Absence of APP713 mutation in Italian and Russian families with schizophrenia. Neuroscience Letters 1994 Jan
3;165(1-2):45-7.

17. Grassi E, Mortilla M, Amaducci L, Pallanti S, Pazzagli A, Galassi F, Guarnieri BM, Petruzzi C, Bolino F, Ortenzi L, Nistico R, De Cataldo S, Rossi A, Sorbi S. No evidence of linkage between schizophrenia and D2 dopamine receptor gene locus in Italian pedigrees. Neuroscience Letters 1996 Mar 15;206(2-3):196-8.

18. Pallanti S, Grecu LM, Gangemi PF, Massi S, Parigi A, Arnetoli G, Quercioli L, Zaccara G. Smooth-pursuit eye movement and saccadic intrusions in obsessive- compulsive disorder. Biological Psychiatry. 1996 Dec 1;40(11):1164-72.

19. Pallanti S, Koran LM. Two case report. CNS Spectrums 1996, vol.1, p.54-57, ISSN: 1092-8529.

20. Bersani G., Saito A. Pallanti S. Sasso E., Tosca P. Clinical variables and response to citalopram in Major Depression: an open multicentric study. Rivista di Psichiatria 32, 260-267, 1997.

21. Pallanti S. Personality Disorders: Myths and Neuroscience. CNS Spectrums
2, 53-63, 1997.

22. Koran LM, Sallee FR, Pallanti S. Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. American Journal of Psychiatry.
1997 Mar;154(3):396-401.

23. Pallanti S, Quercioli L, Pazzagli A. Relapse in young paranoid schizophrenic patients: a prospective study of stressful life events, P300 measures, and coping. American Journal of Psychiatry. 1997 Jun;154(6):792-8.

24. Ramacciotti A, Pallanti S, Pazzagli A. A setting including psychotherapy and psychopharmacological treatment in a case of anorexia nervosa with obsessive compulsive disorder comorbidity. Eating and Weight Disorders. 1997 Dec;2(4):222-
8.

25. Inzitari D, Pantoni L, Lamassa M, Pallanti S, Pracucci G, Marini P. Emotional arousal and phobia in transient global amnesia. Archives of Neurology. 1997
Jul;54(7):866-73.

26. Pallanti S, Quercioli L, Ramacciotti A. Citalopram in anorexia nervosa.
Eating and Weight Disorders. 1997 Dec;2(4):216-21.

27. Pallanti S, Quercioli L, Zaccara G, Ramacciotti AB, Arnetoli G. Eye movement abnormalities in anorexia nervosa. Psychiatry Research. 1998 Mar
20;78(1-2):59-70.

28. Koran LM, Pallanti S, Paiva RS, Quercioli L. Pulse loading versus gradual dosing of intravenous clomipramine in obsessive-compulsive disorder. Eur Neuropsychopharmacol. 1998 May;8(2):121-6.

29. Sallee FR, Koran LM, Pallanti S, Carson SW, Sethuraman G. Intravenous clomipramine challenge in obsessive-compulsive disorder: predicting response to oral therapy at eight weeks. Biological Psychiatry. 1998 Aug 1;44(3):220-7.

30. Pallanti S., Quercioli L. Objective and subjective investigation of cognitive deficits in young schizophrenic patients. Journal of Psychophysiology 13 (3), 203-
203, 1999-01-01.

31. Pallanti S, Koran LM. Citalopram and sexual side effects of selective serotonin reuptake inhibitors. American Journal of Psychiatry. 1999
May;156(5):796. 10327919.

32. Pallanti S, Quercioli L, Pazzagli A. Effects of clozapine on awareness of illness and cognition in schizophrenia. Psychiatry Research. 1999 Jun
30;86(3):239-49.

33. Pallanti S, Quercioli L, Pazzagli A, Rossi A, Dell’Osso L, Pini S, Cassano GB. Awareness of illness and subjective experience of cognitive complaints in patients with bipolar I and bipolar II disorder. American Journal of Psychiatry. 1999
Jul;156(7):1094-6.

34. Pallanti S, Quercioli L, Paiva RS, Koran LM. Citalopram for treatment- resistant obsessive-compulsive disorder. European Psychiatry. 1999 Apr;14(2):101-
6.

35. Pallanti S, Quercioli L, Pazzagli A. Basic symptoms and P300 abnormalities in young schizophrenic patients. Comprehensive Psychiatry. 1999 Sep- Oct;40(5):363-71.

36. Pini S, Dell’Osso L, Mastrocinque C, Marcacci G, Papasogli A, Vignoli S, Pallanti S, Cassano G. Axis I comorbidity in bipolar disorder with psychotic features. British Journal of Psychiatry 1999.467-71.

37. Pallanti S, Quercioli L, Rossi A, Pazzagli A. The emergence of social phobia during clozapine treatment and its response to fluoxetine augmentation. Journal of Clinical Psychiatry. 1999 Dec;60(12):819-23.

38. Di Russo F, Zaccara G, Ragazzoni A, Pallanti S. Abnormal visual event- related potentials in obsessive-compulsive disorder without panic disorder or depression comorbidity. Journal of Psychiatric Research. 2000 Jan-Feb;34(1):75-
82.

39. Pallanti S, Quercioli L. Shame and psychopathology. CNS Spectrums. 2000
Aug;5(8):28-43.

40. Pallanti S, Quercioli L, Pazzagli A. Social anxiety and premorbid personality disorders in paranoid schizophrenic patients treated with clozapine. CNS Spectrums. 2000 Sep;5(9):29-43.

41. Rossi A, Arduini L, Stratta P, Pallanti S. Subjective experience and subjective response to neuroleptics in schizophrenia. Comprehensive Psychiatry.
2000 Nov-Dec;41(6):446-9.

42. Koran LM, Pallanti S, Quercioli L. Sumatriptan, 5-HT(1D) receptors and obsessive-compulsive disorder. European Neuropsychopharmacology. 2001
Apr;11(2):169-72.

43. Hollander E., Bienstock C.A., Koran L.M., Pallanti S., Marazzini D., Rasmussen S.A., Ravizza L., Benkelfat C., saxena S., Greenberg D.B., Sasson Y., Zohar J. Refractory obsessive-compulsive disorder: state-of-the-art treatment. Journal of Clinical Psychiatry 63, 20-29, 12-2001.

44. Pallanti S., Quercioli L. Alternative route of administration and titration of SRIs in anxious resistant patients:Two day-hospital experiences. European Neuropsychopharmacology 11, S312, 2001-12-31.

45. Ramacciotti A, Sorbello M, Pazzagli A, Vismara L, Mancone A, Pallanti S.
Attachment processes in eating disorders. Eat Weight Disord. 2001 Sep;6(3):166-
70.

46. Presta S, Marazziti D, Dell’Osso L, Pfanner C, Pallanti S, Cassano GB.
Kleptomania: clinical features and comorbidity in an Italian sample. Comprehensive
Psychiatry. 2002 Jan-Feb;43(1):7-12.

47. Hollander E, Bienstock CA, Koran LM, Pallanti S, Marazziti D, Rasmussen SA, Ravizza L, Benkelfat C, Saxena S, Greenberg BD, Sasson Y, Zohar J. Refractory obsessive-compulsive disorder: state-of-the-art treatment. Journal of Clinical Psychiatry. 2002;63 Suppl 6:20-9.

48. Pallanti S, Hollander E, Bienstock C, Koran L, Leckman J, Marazziti D, Pato M, Stein D, Zohar J; International Treatment Refractory OCD Consortium. Treatment non-response in OCD: methodological issues and operational definitions. International Journal of Neuropsychopharmacology. 2002 Jun;5(2):181-91.

49. Pallanti S, Quercioli L, Sood E, Hollander E. Lithium and valproate treatment of pathological gambling: a randomized single-blind study. Journal of Clinical Psychiatry. 2002 Jul;63(7):559-64.

50. Pallanti S, Quercioli L, Koran LM. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. Journal of Clinical Psychiatry. 2002 Sep;63(9):796-801.

51. Pallanti S, Baldini Rossi N, Sood E, Hollander E. Nefazodone treatment of pathological gambling: a prospective open-label controlled trial. Journal of Clinical Psychiatry. 2002 Nov;63(11):1034-9.

52. Buchsbaum M.S., Hollander E., Pallanti S., Baldini-Rossi N. Brikman A.M., Platholi J., Sood E. Positron emission tomography. Imaging of risperidone augmentation in SRI-refractory patients. Biological Psychiatry 51 (8), 47S-47S,
2002-04-14.

53. Pallanti S., Rossi N.B., Friedberg J., Hollander E. Psychobiology of Impulse- Control Disorders Not Otherwise Specified (NOS). Biological Psychiatry 2003,
1315-1329.

54. Sood ED, Pallanti S, Hollander E. Diagnosis and treatment of pathologic gambling. Current Psychiatry Reports. 2003 May;5(1):9-15.

55. Hollander E, Baldini Rossi N, Sood E, Pallanti S. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo- controlled study. International Journal of Neuropsychopharmacology. 2003
Dec;6(4):397-401.

56. Pallanti S, Quercioli L, Hollander E. Social anxiety in outpatients with schizophrenia: a relevant cause of disability. American Journal of Psychiatry. 2004
Jan;161(1):53-8.

57. Pallanti S, Quercioli L, Bruscoli M. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. Journal of Clinical Psychiatry. 2004
Oct;65(10):1394-9.

58. Pallanti S, Hollander E, Goodman WK. A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder. Journal of Clinical Psychiatry. 2004;65 Suppl 14:6-10.

59. Hollander E, Pallanti S, Allen A, Sood E, Baldini Rossi N. Does sustained- release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? American Journal of Psychiatry. 2005 Jan;162(1):137-45.

60. Hollander E, Sood E, Pallanti S, Baldini-Rossi N, Baker B. Pharmacological treatments of pathological gambling. Journal of Gambling Studies. 2005
Spring;21(1):99-110.

61. Haznedar MM, Roversi F, Pallanti S, Baldini-Rossi N, Schnur DB, Licalzi EM, Tang C, Hof PR, Hollander E, Buchsbaum MS. Fronto-thalamo-striatal gray and white matter volumes and anisotropy of their connections in bipolar spectrum illnesses. Biological Psychiatry. 2005 Apr 1;57(7):733-42.

62. Urpe M, Pallanti S, Lotti T. Psychosomatic factors in dermatology.
Dermatologic Clinics. 2005 Oct;23(4):601-8.

63. Pallanti S, Lotti T, Urpe M. Psychoneuroimmunodermatology of atopic dermatitis: from empiric data to the evolutionary hypothesis. Dermatologic Clinics.
2005 Oct;23(4):695-701.

64. Hollander E, Pallanti S, Baldini Rossi N, Sood E, Baker BR, Buchsbaum MS.
Imaging monetary reward in pathological gamblers. World Journal of Biological
Psychiatry. 2005;6(2):113-20.

65. Pallanti S, Lassi S, La Malfa G, Campigli M, Di Rubbo R, Paolini G, Cesarali V. Short report: Autistic gastrointestinal and eating symptoms treated with secretin: a subtype of autism. Clinical Practice & Epidemiology in Mental Health. 2005 Nov
15;1:24.

66. Pallanti S, DeCaria CM, Grant JE, Urpe M, Hollander E. Reliability and validity of the pathological gambling adaptation of the Yale-Brown Obsessive- Compulsive Scale (PG-YBOCS). Journal of Gambling Studies. 2005
Winter;21(4):431-43.

67. Rossi A, Rucci P, Mauri M, Maina G, Pieraccini F, Pallanti S, Endicott J; (For the EQUIP group). Reliability and validity of the Italian version of the Quality of Life, Enjoyment and Satisfaction Questionnaire. Quality of Life Research. 2005
Dec;14(10):2323-8.

68. Pallanti S, Quercioli L. Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2006 May;30(3):400-12.

69. Buchsbaum MS, Hollander E, Pallanti S, Baldini Rossi N, Platholi J, Newmark R, Bloom R, Sood E. Positron emission tomography imaging of risperidone augmentation in serotonin reuptake inhibitor-refractory patients. Neuropsychobiology. 2006;53(3):157-68.

70. Pallanti S, Bernardi S, Quercioli L, DeCaria C, Hollander E. Serotonin dysfunction in pathological gamblers: increased prolactin response to oral m-CPP versus placebo. CNS Spectrums. 2006 Dec;11(12):956-64.

71. Pallanti S, Bernardi S, Quercioli L. The Shorter PROMIS Questionnaire and the Internet Addiction Scale in the assessment of multiple addictions in a high- school population: prevalence and related disability. CNS Spectrums.
2006;11(12):966-74.

72. Pallanti S, Quercioli L. Resistant social anxiety disorder response to
Escitalopram. Clinical Practice & Epidemiology in Mental Health. 2006;13;2:35.

73. Hollander E, Kim S, Khanna S, Pallanti S. Obsessive-compulsive disorder and obsessive-compulsive spectrum disorders: diagnostic and dimensional issues. CNS Spectrums. 2007 Feb;12(2 Suppl 3):5-13.

74. Fineberg NA, Pampaloni I, Pallanti S, Ipser J, Stein DJ. Sustained response versus relapse: the pharmacotherapeutic goal for obsessive-compulsive disorder. International Clinical Psychopharmacology 2007;22(6):313-22.

75. Pallanti S, Sandner C. Treatment of depression with selective serotonin inhibitors: the role of fluvoxamine. International Journal of Psychiatry in Clinical Practice. 2007; 11(3): 233-238.

76. Pallanti S. Transcultural observations of obsessive-compulsive disorder.
American Journal of Psychiatry. 2008 Feb;165(2):169-70.

77. Pallanti S, Masetti S, Bernardi S, Innocenti A, Markella M, Hollander E.
Obsessive compulsive disorder comorbidity in DBA. Clinical Practice & Epidemiology in Mental Health. 2008 Mar 10;4:6.

78. La Malfa G, Lassi S, Bertelli M, Pallanti S, Albertini G. Detecting attention- deficit/hyperactivity disorder (ADHD) in adults with intellectual disability The use of Conners’ Adult ADHD Rating Scales (CAARS). Research in Developmental Disabilities. 2008 Mar-Apr;29(2):158-64.

79. Pallanti S. Brain plasticity and brain stimulation in neuropsychiatry: toward individualized medicine. CNS Spectrums. 2008 Apr;13(4):287-92.

80. Hollander E, Buchsbaum MS, Haznedar MM, Berenguer J, Berlin HA, Chaplin W, Goodman CR, LiCalzi EM, Newmark R, Pallanti S. FDG-PET study in pathological gamblers. 1. Lithium increases orbitofrontal, dorsolateral and cingulated metabolism. Neuropsychobiology. 2008;58(1):37-47.

81. Pallanti S, Hollander E. Obsessive-compulsive disorder spectrum as a scientific “metaphor”. CNS Spectrums. 2008 Sep;13(9 Suppl 14):6-15.

82. Berlin H.A., Koran L.M., Jenike M.A., Shapira N.A., Chaplin W., Pallanti S., Hollander E. Double-blind, placebo-controlled trial of topiramate augmentation in the treatment of obsessive-compulsive disorder. Biological Psychiatry 63 (7), 170S-
170S, 2008-04-01.

83. Pallanti S, Bernardi S. Neurobiology of repeated transcranial magnetic stimulation in the treatment of anxiety: a critical review. International Clinical Psychopharmacology 2009 Jul;24(4):163-73.

84. Faravelli C, Lo Sauro C, Castellini G, Ricca V, Pallanti S. Prevalence and correlates of mental disorders in a school-survey sample. Clinical Practice & Epidemiology in Mental Health 2009 Nov 24;5:1-8.

85. Pallanti S, Castellini G, Chamberlain SR, Quercioli L, Zaccara G, Fineberg NA. Cognitive event-related potentials differentiate schizophrenia with obsessive- compulsive disorder (schizo-OCD) from OCD and schizophrenia without OC symptoms. Psychiatry Research. 2009 Nov 30;170(1):52-60.

86. Potenza MN, Koran LM, Pallanti S. The relationship between impulse- control disorders and obsessive-compulsive disorder: a current understanding and future research directions. Psychiatry Research. 2009 Nov 30;170(1):22-31.

87. Bernardi S, Pallanti S. Internet addiction: a descriptive clinical study focusing on comorbidities and dissociative symptoms. Comprehensive Psychiatry. 2009 Nov- Dec;50(6):510-6.

88. Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study. CNS Drugs. 2009 Dec;23(12):1047-55.

89. Lisanby SH, Pallanti S, Schlaepfer TE. FDA considers classification of ECT.
CNS Spectrums. 2009 Dec;14(12):668-70.

90. Pallanti S, Bernardi S, Di Rollo A, Antonini S, Quercioli L. Unilateral low frequency versus sequential bilateral repetitive transcranial magnetic stimulation: is simpler better for treatment of resistant depression? Neuroscience.
2010;5;167(2):323-8.

91. Pallanti S, Bernardi S, Raglione LM, Marini P, Ammannati F, Sorbi S, Ramat S. Complex repetitive behavior: punding after bilateral subthalamic nucleus stimulation in Parkinson’s disease. Parkinsonism and Related Disorder. 2010
Jul;16(6):376-80.

92. Cecchelli C, Grassi G, Pallanti S. Aripiprazole Improves Depressive Symptoms and Immunological Response to Antiretroviral Therapy in an HIV- Infected Subject with Resistant Depression. Case Reports in Medicine.
2010;2010:836214.

93. Schlaepfer TE, Lisanby SH, Pallanti S. Separating hope from hype: some ethical implications of the development of deep brain stimulation in psychiatric research and treatment. CNS Spectrums. 2010 May;15(5):285-7.

94. Pallanti S., Schlaepfer T.E., Lisanby S.H. The Clinical Future of Repetitive Transcranical Magnetic Stimulation and Depression: Separating Hope From Hype. CNS Spectrums 15 (9), 554-557, 2010.

95. Pallanti S, Haznedar MM, Hollander E, Licalzi EM, Bernardi S, Newmark R, Buchsbaum MS. Basal Ganglia activity in pathological gambling: a fluorodeoxyglucose-positron emission tomography study. Neuropsychobiology.
2010;62(2):132-8.

96. Pallanti S. Problematic Internet use: is it more compulsory than rewarding or mood driven? World Psychiatry. 2010 Jun;9(2):96-7.

97. Bernardi S, Cortese S, Solanto M, Hollander E, Pallanti S. Bipolar disorder and comorbid attention deficit hyperactivity disorder. A distinct clinical phenotype? Clinical characteristics and temperamental traits. World Journal of Biological Psychiatry. 2010 Jun;11(4):656-66.

98. Pallanti S, Bernardi S, Allen A, Chaplin W, Watner D, DeCaria CM, Hollander E. Noradrenergic function in pathological gambling: blunted growth hormone response to clonidine. Journal of Psychopharmacology. 2010 Jun;24(6):847-53.

99. Bernardi S, Pallanti S. Successful duloxetine treatment of a binge eating disorder: a case report. Journal of Psychopharmacology. 2010 Aug;24(8):1269-72.

100. Pallanti S, Borgheresi A, Pampaloni I, Giovannelli F, Bernardi S, Cantisani A, Zaccara G, Cincotta M. Motor cortex excitability correlates with novelty seeking in social anxiety: a transcranial magnetic stimulation investigation. Journal of Neurology. 2010 Aug;257(8):1362-8.

101. Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Bruguà M, Carpentier PJ, Edvinsson D, Fayyad J, Foeken K, Fitzgerald M, Gaillac V, Ginsberg Y, Henry C, Krause J, Lensing MB, Manor I, Niederhofer H, Nunes-Filipe C, Ohlmeier MD, Oswald P, Pallanti S, Pehlivanidis A, Ramos-Quiroga JA, Rastam M, Ryffel-Rawak D, Stes S, Asherson P. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry.
2010;3;10:67.

102. Pallanti S. Augmentation strategies in resistant obsessive-compulsive disorders (OCD), International Journal of Psychiatry in Clinical Practice 14, 15-16,
2010-11-01.

103. Pallanti S, Bernardi S, Allen A, Hollander E. Serotonin function in pathological gambling: blunted growth hormone response to sumatriptan. Journal of Psychopharmacology. 2010 Dec;24(12):1802-9.

104. Pallanti S. Unique contributions of brain stimulation to the study of consciousness: where neuroscience meets philosophy. CNS Spectrums. 2010
Mar;15(3):154-6.

105. Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, Hollander E. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. Journal of Clinical Psychiatry.
2011 May;72(5):716-21. *Participated extensively in conception and trial design, participated in drafting, reviewing and critical revision of the manuscript

106. Di Rollo A, Pallanti S. Phantom limb pain: low frequency repetitive transcranial magnetic stimulation in unaffected hemisphere. Case Reports in Medicine. 2011;2011:130751.

107. Bernardi S, Faraone SV, Cortese S, Kerridge BT, Pallanti S, Wang S, Blanco C. The lifetime impact of attention deficit hyperactivity disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Psychological Medicine. 2011 Aug 16:1-13. *Provided study ideas and concept, participated in the drafting and revision of the manuscript, and provided mentorship to first author

108. Pallanti S, Grassi G, Sarrecchia ED, Cantisani A, Pellegrini M. Obsessive- compulsive disorder comorbidity: clinical assessment and therapeutic implications. Front Psychiatry. 2011;2:70.

109. Valenti R, Pescini F, Antonini S, Castellini G, Poggesi A, Bianchi S, Inzitari D, Pallanti S, Pantoni L. Major depression and bipolar disorders in CADASIL: a study using the DSM-IV semi-structured interview. Acta Neurologica Scandinavica. 2011
Dec;124(6):390-5. *Participated extensively in conception and trial design, acquisition, analysis and interpretation of data, participated in drafting, reviewing and critical revision of the manuscript

110. Baldwin DS, Allgulander C, Bandelow B, Ferre F, Pallanti S. An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder. World Journal of Biological Psychiatry. 2012; 13(7):510-6.

111. Moretti S, Arunachalam M, Colucci R, Pallanti S, Kline JA, Berti S, Lotti F, Lotti T. Autoimmune markers in vitiligo patients appear correlated with obsession and phobia. Journal of the European Academy of Dermatology and Venereology.
2012; 26(7):861-7. *Participated extensively in conception and trial design, participated in drafting, reviewing and critical revision of the manuscript

112. Pallanti S, Cantisani A, Grassi G, Antonini S, Cecchelli C, Burian J, Cauli G, Quercioli L. rTMS age-dependent response in treatment resistant depressed subjects: a mini-review, CNS Spectrums (2012), 17, 24-30.

113. S. Pallanti, A. Di Rollo, S. Antonini, E. Hollander and L.Quercioli Low Frequency rTMS over Right Dorsolateral Prefrontal Cortex in the Treatment of Resistant Depression: Cognitive Improvement is Independent from Clinical Response, Neuropsychobiology 2012 Jun; 65(4):227-35.

114. Moretti S., Arunachalam M., Colucci R., Pallanti S., Kline JA., Berti S., Lotti F., Lotti T. Autoimmune markers in vitiligo patients appear correlated with obsession and phobia. Journal of the European Academy of Dermatology and Venereology
2012; 26 (7), 861-867. *Participated extensively in conception, drafting, reviewing and critical revision of the manuscript

115. Bandinelli F, Prignano F, Bonciani D, Pallanti S, Lotti T, Salaffi F, Bartoli F, Candelieri A, Giovannini L, Maddali Bongi S, Matucci-Cerinic M. Clinical and demographic factors influence on anxiety and depression in early psoriatic arthritis (ePsA). Clinical and Experimental Rheumatology. 2012;31(2):318-9. *Participated extensively in conception, drafting, reviewing and critical revision of the manuscript

116. Baldwin DS, Pallanti S, Zwanzger P. Developing a European Research Network to Address Unmet Needs in Anxiety Disorders. Neuroscience and Biobehavioral Reviews. 2013; 37(10 Pt 1):2312-7. *Participated extensively in conception and trial design, participated in drafting, reviewing and critical revision of the manuscript

117. Valenti R, Salvadori E, Pescini F, Poggesi A, Castellini G, Antonini S, Bianchi S, Inzitari D, Pallanti S, Pantoni L., Facial Affect Recognition in CADASIL Patients., Archives of Clinical Neuropsychology 2013;28(1):65-71. *Participated extensively in conception and trial design, participated in drafting, reviewing and critical revision of the manuscript

118. Berlin HA, Braun A, Simeon D, Koran LM, Potenza MN, McElroy SL, Fong T, Pallanti S, Hollander E. A double-blind, placebo-controlled trial of topiramate for pathological gambling. World Journal of Biological Psychiatry. 2013;(2): 121-128.
*Participated extensively in conception and trial design, participated in drafting, reviewing and critical revision of the manuscript

119. Pallanti S, Cantisani A, Grassi G. Anxiety as a core aspect of schizophrenia.
Current Psychiatry Reports. 2013;15(5):354.

120. Dell’Osso B, Benatti B, Buoli M, Altamura AC, Marazziti D, Hollander E, Fineberg N, Stein DJ, Pallanti S, Nicolini H, Van Ameringen M, Lochner C, Hranov G, Karamustafalioglu O, Hranov L, Menchon JM, Zohar J; ICOCS group. The influence of age at onset and duration of illness on long-term outcome in patients with obsessive-compulsive disorder, a report from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS). European Neuropsychopharmacology. 2013 Aug; 23(8):865 71. *Participated extensively in conception and trial design, acquisition and analysis of data, participated in drafting, reviewing and critical revision of the manuscript

121. Pallanti S, Grassi G, Tofani T, Spitoni S. Pharmacological Treatments for Behavioral Addictions: From Behavioral Dimensions to the Research Domain Criteria Based Target. Current Psychopharmacology, 2013; 2(3):183-189.

122. Marras A, Pallanti S. Transcranial magnetic stimulation for the treatment of pharmacoresistant nondelusional auditory verbal hallucinations in dementia. Case Reports in Psychiatry. 2013; 2013:930304.

123. Pallanti S, Hollander E. Pharmacological, experimental therapeutic, and transcranial magnetic stimulation treatments for compulsivity and impulsivity. CNS Spectrums. 2014; 19(1):50-61.

124. Carelli R, Pallanti S. Streptococcal infections of skin and PANDAS.
Dermatologic Therapy. 2014 Jan; 27(1):28-30.

125. Grassi G, Poli L, Cantisani A, Righi L, Ferrari G, Pallanti S. Hypocondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics. CNS Spectrums. 2014; 9(4):340-6.

126. Van Ameringen S, Simpson W, Patterson B, Dell’Osso B, Finebg n, Hollander E, Hranov L, Hranov G, Lochner C, Karamustafalioglu O, Marazziti D, Menchon JM, Nicolini H, Pallanti S, Stein DJ, Zohar, J. Pharmachological treatment strategies in obsessive-compulsive disorder: A cross-sectional view in nine international OCD centers. Journal of Psychopharmacology 2014; 28(6):596-602.
*Participated extensively in conception and trial design, authorship of sections of the manuscript, participated in drafting, reviewing and critical revision of the manuscript

127. Di Rubbo R., Sogaro E., Pallanti, S. Communicative evolutive psychotherapy adapted for the psychodynamic group setting in the treatment of pathological interpersonal dynamics of identity. Dynamische Psychiatrie. 2013; 46(3): 204-233.

128. Pallanti S, Grassi G, Cantisani A. Emerging drugs to treat obsessive- compulsive disorders. Expert opin Emerg Drugs, 2014 Mar; 19(1):66-77.

129. Pallanti S, Grassi G, Antonini S, Quercioli L, Salvadori E, Hollander E. rTMS
in resistant mixed states: An exploratory study. J Affect Disord. 2014; 157:66-71.

130. Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E. Ondasetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation. Eur Neuropsychopharmacol. 2014; 24(3):375-
380.

131. Pallanti S, Grassi G, Ramella Cravaro V, Goodman W.K. From Psychopathology to neurocircuits: what we can learn from DBS? The case of obsessive-compulsive disorder. J. Psychopathol. 2014;20:27-32.

132. Aguglia E, Biggio G, Signorelli MS, Mencacci C; Steering Committee on behalf of the STIMA-D Investigators. Italian Study on Depressive Disorders (STudio Italiano MAlattia Depressiva, or STIMA-D): a nationwide snapshot of the status of treatment for major depression. Pharmacopsychiatry.2014 May;47(3), 105-
10. * Collaborator: Pallanti S. *Acquisition of data

133. Pallanti S, Tofani T, Zanardelli M, Di Cesare mannelli L, Ghelardini C. BDNF and ARTEMIN are increased in drug-naive non-depressed GAD patients: preliminary data. International Journal of Psychiatry in Clinical Practice. 2014;
18(4):255-60.

134. Lochner C, Fineberg NA, Zohar J, Van Ameringen M, Juven_Wetzler A, Altamura AC Cuzen NL, Hollander E, Denys D, Nicolini H, Dell’Osso B, Pallanti S, Stein DJ, Comorbidity in obsessive-compulsive disorder (OCD): a report from the International College of Obsessive-Compulsive Spectrum Disorder (ICOCS). Comprehensive Psychiatry. 2014;55(7):1513-9. *Participated extensively in conception and trial design, drafting, reviewing and critical revision of the manuscript

135. Pallanti S, Grassi G. Pharmacologic treatment of obsessive-compulsive disorder comorbidity. Expert Opin Pharmacother. 2014;15(17):2543-52.

136. Mucci A, Rucci P, Rocca P, Bucci P, Gibertoni D, Merlotti E, Galderisi S, Maj M; Italian Network for Research on Psychoses. The Specific Level of Functioning Scale: construct validity, internal consistency and factor structure in a large Italian sample of people with schizophrenia living in the community. Schizophrenia Research. 2014; 159(1):144-50. *Collaborator: Pallanti S.
*Acquisition of data

137. Galderisi S, Rossi A, Rocca P, Bertolino A, Mucci A, Bucci P, Rucci P, Gibertoni D, Aguglia E, Amore M, Bellomo A, Biondi M, Brugnoli R, Dell’Osso L, De Ronchi D, Di Emidio G, Di Giannantonio M, Fagiolini a, Marchesi C, Monteleone P, Oldani L, Pinna F, Roncone R, Sacchetti E, Santonastaso P, Siracusano A, Vita A, Zeppegno P, Maj M; Italian Network for Research on Psychoses. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. World Psychiatry. 2014; 13(3):275-87.
*Collaborator: Pallanti S. *Acquisition of data

138. Grassi G, Godini L, Grippo A, Piccagliani D, Pallanti S. Enhancing Cognitive- behavioral Therapy with Repetitive Transcranial Magnetic Stimulation in Refractory Obsessive-Compulsive-Disorder: a Case Report. Brain Stimulation. 2015; 8(1):160-
1.

139. Pallanti S, Salerno L. Raising attention to attention deficit hyperactivity disorder in schizophrenia. World Journal of Psychiatry. 2015;5(1):47-55.

140 Dell’Osso B, Nicolini H, Lanzagorta N, Benatti B, Spagnolin G, Palazzo MC, Marazziti D, Hollander E, Fineberg N, Stein DJ, Pallanti S, Van Ameringen M, Lochner C, Hranov N, Karamustafalioglu O, Hranov L, Zohar J, Denys d, Altamura AC, Menchon JM. Cigarette smoking in patients with obsessive compulsive disorder: a report from International College of Obsessive Compulsive Spectrum Disorder (ICOCS). CNS Spectrums. 2015; 20(5):469-73. *Participated extensively in conception, participated in drafting, reviewing and critical revision of the manuscript

141. Uzunova G, Pallanti S, Hollander E. Excitatory/inhibitory imbalance in autism spectrum disorder: Implications for interventions and therapeutics. World Journal of Biological Psychiatry. 2015;15:1-13. *Authorship of sections of the manuscript, participated in drafting, reviewing and critical revision of the manuscript

142. Grant J E, Fineberg N, Van Ameringen A, Cath D, Visser H, Carmi L,
Pallanti S, Hollander E, Van Balkom A J, New treatment models for compulsive disorders. European Neuropsychopharmacology 2016; 26(5):877-84. *Participated extensively in conception, acquisition of data, authorship of sections of the manuscript

143. Grassi G, Pallanti S, Righi L, Figee M, Mantione M, Denys D, Piccagliani D, Rossi A, Stratta P. Think twice: Impulsivity and decision making in obsessive- compulsive disorder. Journal of Behavioral Addiction 2015;4(4):263-72. *Provided study ideas, participated in the drafting, reviewing and revision of the manuscript, and provided mentorship to first author

144. Pallanti S, Marras A, Salerno L, Makris N, Hollander E. Better than treated as usual: Transcranial magnetic stimulation augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder, mini-review and pilot open-label trial. Journal of Psychopharmacology. 2016; 30(6):568-78.

145. Menchon JM, Van Ameringen M, Dell’Osso B, Denys D, Figee M, Grant JE, holander E, Marazziti D, Nicolini H, Pallanti S, Ruck R, stein DJ, Andersson E, bipeta R, Cath DC, drummond L, Feusner J, Geller DA, Hranov , lochner C, Matsunaga H, McCabe RE, Mpavaenda D, Nakamae T, O’Kearney R, pasquini M, Perez Rivera R, Poyurovsky M, Real E, do Rosario MC, Sreni N, Swinson RP, Vulink N, Zphar J, Fineberg N. Standards of care for obsessive-compulsive disorders centres. International Journal of Psychiatry in Clinical Practice.
2016;20(3):204-8. *Participated extensively in conception and trial design, acquisition of data and in drafting

146. Marras A, Fineberg N, Pallanti S. Obsessive compulsive and related disorders: comparing DSM-5 and ICD-11. CNS Spectrums. 2016;21(4):324-33.

147. Bandelow B, Baldwin D, Abelli M, Bolea-Alamanac B, bourin M, Chamberlain SR, Cinosi E, Davies S, Domscchke K, Fineberg N, Grunblatt E, Jarema M, Kim YK, Maron E, Masdrakis V, Mikova O, Nutt D, Pallanti S, Pini S, Strohle A, Thibaut F, Vaghi MM, Won E, Wedekind D, Wichniak A, Woolley J, Zwanzger P, Riederer P. Biological markers for anxiety disordrs, OCD and PTSD: a consensus statement. Part II: Neurochemistry, neurophisiology and neurocognition. World Journal of Biological Psychiatry. 2016;15:1-53. *Participated extensively in conception and trial design, acquisition,authorship of sections of the manuscript

148. Dell’Osso B, Benatti B, Hollander E, Fineberg N, Stein DJ, Lochner C, Nicolini H, Lanzagorta N, Palazzo C, altamura AC, Marazziti D, Pallanti S, Van Ameringen M, Karamustafalioglu O, Drummond LM, Hrano L, Figee M, Grant JE, Zohar J, Denys D, Menchon JM. Childhood, adolescent and adult age at onset and related clinical correlates in obsessive-compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). International Journal of Psychiatry in Clinical Practice. 2016;19:1-8. *Participated extensively in conception and trial design, acquisition of data and in drafting

149. Pallanti S. ICD and DSM: Neuroplasticity and Staging are still missing. CNS Spectrums. 2016 Aug:21(4):276-8.

150. Galderisi S, Rossi A, Rocca P, Bertolino A, Mucci A, Bucci P, Rucci P, Gibertoni D, Aguglia E, Amore M, Blasi G, Comparelli A, Di Giannantonio M, Goracci A, Marchesi C, Monteleone P, Montemagni C, Pinna F, Roncone R, Siracusano A, Stratta P, Torti MC, Vita A, Zeppegno P, Chieffi M, Maj M; Italian Network for Research on Psychoses. Pathways to functional outcome in subjects with schizophrenia living in the community and their unaffected first degree relatives. Schizophr Res 2016; 175(1-3):154-60. *Collaborator: Pallanti S.
*Participated extensively in conception and trial design, acquisition, analysis of data, reviewing and critical revision of the manuscript

151. Rocca P, Galderisi S, Rossi A, Bertolino A, Rucci P, Gibertoni D, Montemagni C, Sigaudo M, Mucci A, Bucci P, Acciavatti T, Aguglia E, Amore M, Bellomo A, De Ronchi D, Dell’Osso L, Di Fabio F, Girardi P, Goracci A, Marchesi C, Monteleone P, Niolu C, Pinna F, Roncone R, Sacchetti E, Santonastaso P, Zeppegno P, Maj M; Italian Network for Research on Psychoses. Social cognition in people with schizophrenia: a cluster-analytic approach. Psychol Med
2016 Oct;46(13):2717-2729 *Collaborator: Pallanti S. *Participated extensively in conception and trial design, acquisition, participated in drafting, reviewing and critical revision of the manuscript

152. Menchón JM, van Ameringen M, Dell’Osso B, Denys D, Figee M, Grant JE, Hollander E, Marazziti D, Nicolini H, Pallanti S, Ruck C, Shavitt R, Stein DJ, Andersson E, Bipeta R, Cath DC, Drummond L, Feusner J, Geller DA, Hranov G, Lochner C, Matsunaga H, McCabe RE, Mpavaenda D, Nakamae T, O’Kearney R, Pasquini M, Pérez Rivera R, Poyurovsky M, Real E, do Rosário MC, Soreni N, Swinson RP, Vulink N, Zohar J, Fineberg N. Standards of care for obsessive- compulsive disorder centres. Int J Psychiatry Clin Pract. 2016 Sep;20(3):204-8.
*Participated extensively in conception and trial design, acquisition of data and in drafting, reviewing and critical revision of the manuscript

153. Giordano F, Cavallo M, Spacca B, Pallanti S, Tomaiuolo F, Pieraccini F, Fagiolini A, Grandoni M, Melani F, Zicca A, Sestini S, Genitori L. Deep Brain Stimulation of the Anterior Limb of the Internal Capsule May Be Efficacious for Explosive Aggressive Behaviour. Stereotact Funct Neurosurg. 2016 Nov
1;94(6):371-378. *Participated extensively in conception and trial design, acquisition of data and in drafting

154. Dell’Osso B, Benatti B, Hollander E, Fineberg N, Stein DJ, Lochner C, Nicolini H, Lanzagorta N, Palazzo C, Altamura AC, Marazziti D, Pallanti S, Van Ameringen M, Karamustafalioglu O, Drummond LM, Hranov L, Figee M, Grant JE, Zohar J, Denys D, Menchon JM. Childhood, adolescent and adult age at onset and related clinical correlates in obsessive-compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). Int J Psychiatry Clin Pract. 2016 Nov;20(4):210-7. *Participated extensively in conception and trial design, acquisition of data and in drafting, reviewing and critical revision of the manuscript

155. Grassi G, Micheli L, Di Cesare Mannelli L, Compagno E, Righi L, Ghelardini C, Pallanti S. Atomoxetine for hoarding disorder: A pre-clinical and clinical investigation. J Psychiatr Res. 2016 Dec;83:240-248.

156. Chiariello F, Spitoni S, Hollander E, Pallanti S. An expert opinion on PANDAS/PANS: highlights and controversies. International Journal of Psychiatry in Clinical Practice 2017; 1-8 Published online: 13 Feb 2017

157. Salerno L, Makris N, Pallanti S. Sleep disorders in adult ADHD: a key feature. Journal of Psychopathology 2016;22:135-140.

158. Pallanti S. Biological Markers for Anxiety Disorders, OCD and PTSD – A Consensus Statement – Part II: Neurochemistry, Neurophysiology and Neurocognition. The World Journal of Biological Psychiatry World J Biol Psychiatry.
2017 Apr;18(3):162-214.

159. Dell’Osso B, Benatti B, Arici C, Palazzo C, Altamura AC, Hollander E, Fineberg N, Stein DJ, Nicolini H, Lanzagorta N, Marazziti D, Pallanti S, van Ameringen M, Lochner C, Karamustafalioglu O, Hranov L, Figee M, Drummond L, Rodriguez CI, Grant J, Denys D, Menchon JM, Zohar J. Prevalence of suicide attempt and clinical characteristics of suicide attempters with obsessive-compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). CNS Spectr. 2017 Mar 16:1-8.

160. Dell’Osso B, Marazziti D, Albert U, Pallanti S, Gambini G, Tundo A, Zanaboni C, Servello D, Rizzo R, Scalone L, Benatti B, Altamura C, Porta M. Parsing the phenotype of obsessive-compulsive tic disorder (OCTD): a multidisciplinary consensus. Int J Psychiatry Clin Pract. 2017 Jun;21(2):156-159.

Peer-Reviewed Editorials

1. Pallanti S. The anxiety-psychosis spectrum. CNS Spectrums. 2000
Sep;5(9):22.

2. Pallanti S., Transcultural Observations of Obsessive-Compulsive disorder, American Journal of Psychiatry, 165:2, February 2008

3. Pallanti S., Problematic Internet Use: is it more compulsory than rewarding or mood driven? World Psychiatry.2010 Jun;9(2):96-7.

4. Pallanti S. Transcultural observations of obsessive-compulsive disorder.
American Journal of Psychiatry. 2008 Feb;165(2):169-70.

5. Pallanti S. Problematic Internet use: is it more compulsory than rewarding or mood driven? World Psychiatry. 2010 Jun;9(2):96-7.

6. Grassi G, Godini L, Grippo A, Piccagliani D, Pallanti S. Enhancing Cognitive- behavioral Therapy with Repetitive Transcranial Magnetic Stimulation in Refractory Obsessive-Compulsive-Disorder: a Case Report. Brain Stimulation.2014.10.18.

Peer-Reviewed Abstracts

1. Pallanti S., Zuccarini S., Rivelli A., Quercioli L., Pazzagli A. Depth perception in schizophrenia. Biological Psychiatry 35 (9), 637-638. 1994-05-01.

2. Koran L., Sallee F., Pallanti S., Paiva R., Quercioli L. Intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Psychopharmacology Bulletin 32 (3), 466-466. Nov. 1996.

3. Di Russo F., Zaccara G., Pallanti S., Gangemi P., Lori S., Ragazzoni A. Visual event-related potentials in obsessive-compulsive disorders. Electroencephalography and Clinical Neurophysiology 103 (1), 211-211, Jul 1997.

4. Pallanti S., Quercioli L. Objective and subjective investigation of cognitive deficits in young schizophrenic patients. Journal of Psychophysiology 13 (3), 203-
203, 1999-01-01.

5. Russo F., Zaccara G., Ragazzoni A. Pallanti S. Abnormal visual ERPs in obsessive-compulsive deficits in young schizophrenic patients. Journal of Psychophysiology 13 (3), 207-207, 1999-01-01.

6. Pallanti S., Quercioli L. Reboxetine in bulimia nervosa: An open study.
Biological Psychiatry 49 (8), 105S-106S. 2001-04-05.

7. Quercioli L., Bruscoli M., Pallanti S. P.1.030 Mirtazapine augmentation of citalopram response in OCD patients without comorbid depression: A pilot study. European Neuropsychopharmacology 14, S186, 2004-10-31.

8. Pallanti S., Quercioli L. Reboxetine in bulimia nervosa: An open study.
Biological Psychiatry 49 (8), 105S-106S. 2001-04-05.

9. Quercioli L., Bruscoli M., Pallanti S. P.1.030 Mirtazapine augmentation of citalopram response in OCD patients without comorbid depression: A pilot study. European Neuropsychopharmacology 14, S186, 2004-10-31.

10. Pallanti S., Baker B.R., Chaplin W., Kim S., De Caria C., Bernardi S., Hollander E., Noradrenergic function in pathological gambling. Biological Psychiatry. 2006;59 (8), 32S-32S.

11. Bernardi S., Ramat S., Raglione L., Marini P., Sorbi S., Ammannati F., Pallanti S. Punding after bilateral subthalamic nucleus stimulation in Parkinson’s disease. European Psychiatry 23, S350-S351.

12. Cincotta M., Borgheresi A., Pampaloni I., Giovannelli F., Bernardi S., Cantisani A., Zaccara G., Pallanti S. P27-7 Motor cortex excitability correlates with novelty seeking in social anxiety: a transcranial magnetic stimulation study. Clinical Neurophysiology 121, s265, 2010-20-31.

Peer-Reviewed Letters and Commentary

1. Marazziti D, Pallanti S. Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder. American Journal of Psychiatry. 1999
Nov;156(11):1834-5.

2. Pallanti S. “Dr. Pallanti Replies.” American Journal of Psychiatry, 2000
157(5):840-a–840.

3. Hollander E, Pallanti S. “5-HT1D Function and Repetitive Behaviors.” American Journal of Psychiatry, 2001 158(6):972-a–973.

4. Pallanti S, Quercioli L, Hollander E. “Dr. Pallanti and Colleague Reply.” American Journal of Psychiatry, 2005 162(2): 400-a–401.

5. Faravelli C., Pallanti S., Biondi F., Paterniti S., Scarpato M.A. Dr. Faravelli and
Associates Reply. American Journal of Psychiatry 150 (9), 1437-1437. 1993-09-01.

6. Grassi G, Figee M, Stratta P, Rossi A, Pallanti S. Response to Cognitive impulsivity and the behavioral addiction model of obsessive-compulsive disorder: Abramovitch and McKay (2016). J Behav Addict. 2016 Sep;5(3):398-400.

7. Koran LM, Faravelli C, Pallanti S. Intravenous clomipramine for obsessive- compulsive disorder. Journal of Clinical Psychopharmacology 1994 Jun;14(3):216-8

8. Marazziti D, Pallanti S. Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder. American Journal of Psychiatry. 1999
Nov;156(11):1834-5.

9. Hollander E, Pallanti S. 5-HT(1D) function and repetitive behaviors. American
Journal of Psychiatry. 2001 Jun;158(6):972-3.

10. Pallanti S, Koran LM. Citalopram and sexual side effects of selective serotonin reuptake inhibitors. American Journal of Psychiatry. 1999 May;156(5):796.

Peer-Reviewed Book Reviews

1. Pallanti S. Obsessive-Compulsive Disorder: Theory, Research, and Treatment.
American Journal of Psychiatry 1999;156:1108a-1109.

2. Pallanti S. Panic Disorder: Clinical Diagnosis, Management and Mechanism.
American Journal of Psychiatry 158(7), 1176-a-1177. 2001-07-01. Book Review

3. Pallanti S. Panic Disorder: Clinical Diagnosis, Management and Mechanism.
American Journal of Psychiatry 158(7), 1176-a-1177. 2001-07-01.

4. Pallanti S. Review of perfectionism: theory, research and treatment. American
Journal of Psychiatry 2004, vol.161 (8).

Other Publications

1. Pallanti S. Vincenzo Chiarugi, 1759-1820. American Journal of Psychiatry.
1996 Jul;153(7):944.

2. Pallanti S. Images in Psychiatry. Ugo Cerletti. 1877-1963 Essay. American
Journal of Psychiatry 156.630-630, 1999.

3. Pallanti S. Obsessive-Compulsive Disorder: Theory, Research, and Treatment.
American Journal of Psychiatry 1999;156:1108a-1109

4. Pallanti S., Quercioli L. SSRIs in the treatment of premenstrual dysphoric disorder. Nefazodone: An open trial. European Neuropsychopharmacology 10(S3),
127-128, 2000-09-30

5. Pallanti S. From impulse-control disorders toward behavioral addictions. CNS Spectrums. 2006;11(12).921-922.

6. Pallanti S. Unique contributions of brain stimulation to the study of consciousness: where neuroscience meets philosophy. CNS Spectrums. 2010
Mar;15(3):154-6.

7. Pallanti S., Book Review: Comprehensive care of schizophrenia: a textbook of clinical management, 2nd edition. American Journal of Psychiatry. 2013 Jan
1;170(1):125-126.

8. Pallanti S., Strategies for Treatment Resistant OCD, Psychiatric Times. 2014.

Book Chapters

1. Pallanti S., Rossi L., De Palma G., Checchi M., Muscas C., Faravelli C.
Electroencephalogram mapping in sodium lactate-induced panic attacks: Preliminary results. Imaging of the Brain in Psychiatry and Related Fields, pp
281-284, Edited by K. Maurer, Springer, 1993

2. Current and Experimental Therapeutics of Obsessive Compulsive Disorders, pp 1647 – 1664, Neuropsychopharmacology: The Fifth Generation of Progress, An Official Publication of the American College of Neuropsychopharmacology, Edited by K.L. Davis, D. Charney, J.T. Coyle and C. Nemeroff, Lippincott/Williams and Wilkins, 2002

3. Psychobiology of Impulse Control Disorders Not Otherwise Specified (NOS), pp
1315 – 1329, Biological Psychiatry, Edited by H. D’Haenen, J.A. den Boer, P. Willner, John Wiley & Sons Ltd., 2002

4. Sood E, Pallanti S, Hollander E. Serotonin reuptake inhibitors in the treatment of pathological gambling. Essential Psychopharmacology, pp 157-169, Edited by R. Murray, Cambridge University Press, 2002

5. Pharmacological Treatments, pp 189 – 200, Pathological Gambling: A Clinical Guide to Treatment, Edited by J. E. Grant, M. Potenza, American Psychiatric Publishing, 2004

6. Pathological Gambling, pp 251 – 289, Clinical Manual of Impulse Control
Disorders, Edited by E. Hollander, D. Stein, American Psychiatric Publishing, 2006

7. Approaches to treatment resistance, pp. 99-117, Obsessive Compulsive
Disorder: Current Science and Clinical Practice, Edited by J. Zohar, John Wiley
& Sons, LTD, 2012

8. Pharmacological treatment of Autism Spectrum Disorders, pp. 151 – 166, Autism Spectrum Disorders- Phenotypes, Mechanisms and treatment , Edited by M. Leboyer, P. Chaste, Karger Medical and Scientific Publishers, 2015

9. New Technologies in Autism: Non-invasive Brain Stimulation, Autism Spectrum Disorders, Enticott PG, Pallanti S, Ring R, Pascual-Leone A, Hollander E., Edited by E. Hollander, D. Fein, P.J. Hagerman. Karger Medical and Scientific Publishers, 2017

10. Incompleteness and Harm Avoidance in OCD, Chapter 9, Obsessive- Compulsive Disorder – Phenomenology, Pathophysiology and Treatment, Pallanti S, Barns J, Pittenger C, Eisen, J., Edited by Pittenger C. Oxford University Press,
2017

Books

1. Pallanti S., Vivere con le Voci, Vivere nel Silenzio, (Live with Voices, Live in
Silence, La nuova Italia Scientifica (1996)

2. Fossi G., Pallanti S., Manuale di Psichiatria (Manual of Psychiatry), Casa
Editrice Ambrosiana, Milano (1993)

3. Pallanti S., Koran L. M., Treatment of OCD Resistant Patients, Airon (2003)

4. Pallanti S., Bruscoli M., Le Emergenze Psichiatriche in Medicina, (Psychiatric Emergency in Medicine) Lippincott /Williams and Wilkins, (2006) sold exclusively by Innova Pharma SpA, Milano

5. Fossi G., Pallanti S., Psichiatria Elementare (Elementary Psychiatry), La
Nuova Italia Scientifica S.p.A. Roma. First edition 1993, 6th edition 2008

6. Pallanti, S. and Lauriello, J., Clinical Manual for Schizophrenia, Edited by B.
Hales, American Psychiatric Publishing. (2010)

7. Pallanti, S. and Formosa, A., Stress? No grazie, siamo resiliente, (Stress? No
Thank you, We are resilient) Trevisini Editore. (2011)

8. Pallanti, S. and Lauriello, J., Editors., Clinical Manual for Treatment of
Schizophrenia, American Psychiatric Publighins. (2011)

9. Pallanti, S., Oltre la Schizophrenia (Beyond Schizophrenia) Edra LSWR (2015)

10. Fossi, G., Pallanti, S., Psichiatria Elementare (Elementary Psychiatry), Carocci
Editori, First edition 1999, Reprint 2015

11. Pallanti, S., Psichiatria Elementare – Oltre il DSM-5 (Elementary Psychiatry – Beyond DSM-5), Carocci Editori, (2017)

Editor for an Italian Edition Book

BAARS-IV (Barkley Adult ADHD Rating Scale-IV), Russell A. Barkley, Hogrefe (2017),
Pallanti S., Salerno L.

The American Psychiatric Publishing Textbook of Psychiatry, Edited by R. E. Hales, S. C. Yudofsky, L. W. Roberts, Sixth Edition, Edra (2014). Manuale di Psichiatria, Editors: Sacchetti E., Mencacci C., Aguglia E., Albert U., Altamura C., Bogetto F., Clerici M., Colombo C., Pallanti S., Santonastaso P., Smeraldi E., Zanalda E., Zuddas A.

Digital Publications

2009 – 2013 CD-ROM for the the Managing Anxiety in Practice (MAP) educational programme

Thesis

1. Pallanti S. (1983) Life events and Depression, Dissertation thesis for Medical Doctorate Degree and European Medical License, University of Florence, School of Medicine, Florence, Italy.

2. Pallanti S. (1987) Life events and Schizophrenia, Dissertation thesis for PhD in
Psychiatry, University of Florence, School of Medicine, Florence, Italy.

3. Pallanti S. (1992) Contingent Negative Variation (CNV) in normal elderly population, Dissertation thesis for PhD in Neurophysiopathology, University of Florence, School of Medicine, Florence, Italy.

EDITORIAL SERVICE

Editorial Board Memberships

Since 2000 Eating and Weight Disorders

Since 2006 Journal of Gambling Studies

Since 2010 Austin Child & Adolescent Psychiatry

Since 2012 CNS Spectrums – International Journal of Neuropsychiatric Medicine

Since 2012 Frontier: Editorial Committee

Since 2012 Giornale Italiano di Psicopatologia

Since 2014 British Association for Psychopharmacology Journal Since 2014 International Journal of Psychiatry in Clinical Practice Since 2016 Journal of Addiction and Therapy
Since 2016 Journal of Psychiatry & Mental Disorders

Since 2016 SM Journal of Psychiatry & Mental Health

Editor/Editor in Chief

2000 & 2006 CNS Spectrums – International Journal of Neuropsychiatric Medicine: Guest
Editor

2008 – 2010 American Journal of Psychiatry Italian edition: Editor in Chief

2016 Annals of Behavioral Addiction: Editor (to be published)

Since 2017 CNS Spectrums – International Journal of Neuropsychiatric Medicine: Field
Editor

International Advisor

2008 – 2012 American Psychiatric Publishing

Reviewer

Since 2000 American Journal of Psychiatry

Since 2000 JAMA of Psychiatry

Since 2000 Journal of Psychiatric Research

Since 2002 Biological Psychiatry

Since 2004 Journal of Clinical Psychiatry

Since 2006 European Neuropsychopharmacology

Since 2010 Lancet

Since 2010 Progress in Neuro-Psychopharmacology & Biological Psychiatry

Since 2010 Psychiatry Research

GRANTS
Current Funding as Principal Investigator

2012 -2018 Phase IV “A non-interventional prospective cohort study of patients with persistent symptoms of schizophrenia to describe the course and burden of illness. Italian Society for Psychopathology 2012; Phase II “A phase 2, randomized, double-blind, placebo controlled study to evaluate the effect pf add-on AMG 747 on schizophrenia negative symptom” AMGEN, Clinical Trial NCT01568229

2017 – 2019 R21 Grant, The National Institute of Mental Health: “Modulating Inhibitory Control Networks in Gambling Disorder with Theta Burst Stimulation”. MPI: Nikolaos and Mukris; Role: Co-I.

Research Funding Under Review

PRIN GRANT -Italian Ministry of Education for University and Research: “Repetitive Transcranial Magnetic Stimulation targeting inhibitory control networks in Anorexia Nervosa” PI: Pallanti

ERA-NET NEURON (Call for transnational research projects 2016 – ‘European Research Projects on External Insults to the Nervous System’) ”Role of repetitive Transcranial Magnetic Stimulation (rTMS) in Protease-Activated Receptor 1 (PAR1)-mediated alterations in synaptic plasticity for the treatment of traumatic brain injury sequels.” Plast4TBI, PI: Pallanti (for Italy)

Past Research Funding as Principal Investigator

2005 RESEARCH FUND, research on “Transcranial Magnetic Stimulation in
Resistant Depression”, Italian Ministry of Health

2007 PRIN GRANT, research on Panic Disorder, Italian Ministry of Education for
University and Research

2009 Ondansetron Augmentation in Treatment Resistant Obsessive-Compulsive Disorder, A single-blind, prospective study. Transcept Pharmaceuticals Inc. (CA), USA

2009 GRANT for Collaboration agreement of Leland Stanford Junior University and University of Florence, Italian Ministry of Education for University and Research

2009 Efficacy of Agomelatine, A randomised double-blind, placebo-controlled, parallel groups, international study. SERVIER INTERNATIONAL, France

2010 International Multicenter Snapshop Study of OCD patients. INTERNATIONAL COLLEGE OF CLINICAL OCD (ICOCS)

2012 Phase II “A randomized, double-blind study comparing the eficacy and safety of tradozone OAD and venlafaxine XR in the treatment of patients with Major Depressive Disorder” ANGELINI

2012 Lurasidone: A 12-week multicenter open label study in subjects with Schizophrenia. LATUDA 2011 Phase III “Double blind placebo controlled trial of Armodafinil in the treatment of Bipolar Depression” TEVA, Clinical Trial NCTO1072929

SERVICES AS MEMBER OF GRANT REVIEW COMMITTEE

2011 Member of Research Funding Evaluation Committee, UK General Medical
Research Council

Since 2011 Member of the Board of Research Funding Evaluation Committee
SAMENTA, Agence Nationale dela Recherche, Paris, France

2013 Member of the Expert Review Board, The ERA-NET scheme of the European Commission ‘Network of European Funding for Neuroscience Research’ (NEURON) for its funding initiative “European Research Projects on Mental Disorders”

PRESENTATIONS
International Meetings

2002 Course Director, Chairman and Invited Speaker (Florence) European Certificate, International Master in Affective Neuroscience “Attentional Dysfunction in OCD Spectrum”

2003 Course Director, Chairman and Invited Speaker (Florence) European Certificate, International Master in Affective Neuroscience “OCD and ADHD: a translational approach ”

2004 Member of the Board of Directors and Invited Speaker International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS) “Resistant OCD: Hoarding and attentional dysfunction ”

2004 Organizer, Course Director, Chairman and Invited Speaker (Florence) Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS “Anxiety and Impulsivity”

2004 Course Director, Chairman and Invited Speaker (Florence) European Certificate, International Master in Affective Neuroscience “OCD spectrum and comorbidities”

2004 Member of the Board of Directors and Invited Speaker International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS) “Neuromodulation for OCD: new targets ”

2004 Poster Award European College of Neuropsychopharmacology (ECNP) “Mirtazapine augmentation of citalopram response in OCD patients without comorbid depression: A pilot study”

2005 Lecturer Stand Alone Lecture Tour in Japan on “New Vision of Pharmacological Intervention for the Acute Psychotic Patient” (Tokyo, Yamanashi, Iwate and Kobe)

2005 Invited speaker European College of Neuropsychopharmacology (ECNP) (Paris) “Treatment-resistant Obsessive Compulsive Disorder : atranslational vision”

2005 Invited Speaker at World Psychiatric Association (WPA) “Improving remission in depression in Mediterranean countries”

2005 Course Director, Chairman and Invited Speaker (Florence) European Certificate, International Master in Affective Neuroscience “Treatment of difficult OCD”

2005 Member of the Board of Directors and Invited Speaker International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS) “Accelerating response to treatment of OCD”

2005 Organizer, Course Director, Chairman and Invited Speaker (Florence) Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS “Compulsivity-impulsivity and Pathological Gambling”

2006 Invited Speaker European College of Neuropsychopharmacology (ECNP)
(Amsterdam) “Gambling as compulsive disorder”

2006 Invited Speaker at World Psychiatric Association (WPA) “Anxiety
Comorbidities and Role of Emotion in Endophenotype of Schizophrenia”

2006 Invited Speaker (Florida) American College of Neuropsychopharmacology “Ondansetron augmentation in treatment- resistant obsessive-compulsive disorder”

2006 Lecturer Solvay Pharmaceuticals Middle East Symposium (Beirut) “Social anxiety disorder : Assessment and treatment with SSRI “

2006 Invited Speaker International Anxiety Disorders Conference (Cape Town)
“Resistant social anxiety disorder : how to get response ”

2006 Course Director, Chairman and Invited Speaker (Florence) European Certificate, International Master in Affective Neuroscience “Pharmacological challenge in OCD”

2006 Member of the Board of Directors and Invited Speaker International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS) “OCD: Anxiety or addictive disorder?”

2006 Organizer, Course Director, Chairman and Invited Speaker (Florence) Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS “Treatment of psychiatric disorder in the Day Hospital”

2007 Invited Speaker at World Psychiatric Association (WPA) “Residual symptoms in depression”

2007 Course Director, Chairman and Invited Speaker (Florence) European Certificate, International Master in Affective Neuroscience “Children with OCD: How to detect and treat”

2007 Member of the Board of Directors and Invited Speaker International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS) “Glutamate pathway in OCD”

2007 Organizer, Course Director, Chairman and Invited Speaker (Florence) Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS “Emotional endophenotype and schizophrenia”; “Resistant Depression: new treatment options”

2007 Invited Speaker, ECNP Targeted Expert Meetings (TEM) Participant
(Vienna) “Behavioral and substance addictions: a new category”

2007 Spokesman and Lecturer (Web Conference with Japan) Eli Lilly Web Conference Marketing in Japan “Treatment of Acute Psychosis and Schizophrenia”

2008 Chairman of Symposium, ECNP TEM Meetings Participant, (Barcelona)
“Dopamine and behavioral addictions”

2008 Course Director, Chairman and Invited Speaker (Florence) European Certificate, International Master in Affective Neuroscience “Endophenotype of impulsive-obsessive spectrum?”

2008 Chairman and Invited Speaker, International Forum on Mood and Anxiety
Disorders (IFMAD) (Vienna) “ Is there an impulsive-obsessive spectrum?”

2008 Member of the Board of Directors and Invited Speaker International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS) “Social Anxiety in OCD disorders”

2008 Organizer, Course Director, Chairman and Invited Speaker (Florence) Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS “PANDAS: assessment and treatment”

2008 Chairman and Speaker at Dinner Symposium on “Impulsive-Compulsive Spectrum Disorders: Diagnostic Issues”, American Psychiatric Association (APA) (Washington DC) “Pharmacological treatments of pathological gambling”

2008 Plenary Lecture World Psychiatric Association (WPA) “Adherence to treatment”

2009 Speaker at American Psychiatric Association (APA) “Unilateral low frequency versus sequential bilateral rTMS: is simpler better for treatment of resistant depression?”

2009 Lecturer Stand Alone Lecture Tour in Japan on “New Vision of Pharmacological Intervention for the Acute Psychotic Patient” (Tokyo, Aomori, Gumma, Tokushima, Fukuoka and Kobe) “Acute schizophrenia”

2009 Course Director, Chairman and Invited Speaker (Florence) European Certificate, International Master in Affective Neuroscience “PANDAS and PANS”

2009 Member of the Board of Directors and Invited Speaker International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS) “Depression, OCD and neuroinflammation”

2009 Organizer, Course Director, Chairman and Invited Speaker (Florence) Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS “Farmaci oltre lo studio STAR”; “Neuroimaging of Pathological Gambling”

2009 Chairman and Invited Speaker, TEM Meetings participant, Plenary Lecture European College of Neuropsychopharmacology (ECNP) (Istanbul) “Pharmacological challenge in OCD and gambling disorder”

2009 Invited Speaker and co-chair of Symposium World Psychiatric Association
(WPA) (Florence) “Behavioral addictions, impulsivity and OCD”

2009 Lecturer Solvay Pharmaceuticals Middle East Symposium (Beirut)
“Treatment of depression with selective serotonin inhibitors”

2009 Invited Speaker International Anxiety Disorders Conference (Amsterdam) “OCD : beyond Anxiety disorders”

2009 Course Director and Invited Speaker (Berlin, London, Athens, Rome, Munich and Paris) MAP – Managing Anxiety in Practice – Pfizer International “Management and treatment of GAD”

2009 Invited Speaker XV Update In Psychiatry (Vienna) “Range of obsessive- compulsive disorders”

2009 Invited Speaker International Anxiety Disorders Conference (Amsterdam)
“OCD anxiety affective condition”

2010 Chairman and invited speaker, TEM Meetings participant , Plenary Lecture (Amsterdam) European College of Neuropsychopharmacology (ECNP) “Ondansetron augmentation in Treatment-Resistant OCD (TR-OCD): Relapse in Y-BOCS symptoms following discontinuation of ondansetron”

2010 Course Director, Chairman and Invited Speaker (Florence) European Certificate, International Master in Affective Neuroscience “Approaches to Treatment Resistance in OC Spectrum”

2010 Chairman and Invited Speaker, International Forum on Mood and Anxiety
Disorders (IFMAD) (Vienna) “Augmentation strategies in resistant OCD”

2010 Course Director and Invited Speaker (Berlin, London, Athens, Rome, Munich and Paris) MAP – Managing Anxiety in Practice – Pfizer International “Comorbid Anxiety in Bipolar Disorder and Psychotic Disorders: Impact on Outcome” “Managing Anxiety in Practice. Generalised Anxiety Disorder: The Hidden Companion”,

2010 Member of the Board of Directors and Invited Speaker International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS) “PANDAS and PANS: is there an inflammation in OCD?”

2010 Organizer, Course Director, Chairman and Invited Speaker (Florence) Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS “Trauma e Psicopatologia nella Vita Quotidiana”, “La Stimolazione Magnetica Transcranica nella depressione”, “Valutazione e trattamento della comorbidità per ansia nelle psicosi”, “Contributi della Stimolazione Magnetica Transcranica allo studio della consapevolezza:dove la Neuroscienza incontra la Filosofia”

2010 Chairman of the TEM meetings and Invited speaker (Paris) European College of Neuropsychopharmacology (ECNP) “Ondansetron augmentation in Treatment-Resistant OCD: Twelve Week, Single-blind, Prospective Study Data”

2010 Lecturer Solvay Pharmaceuticals Middle East Symposium (Beirut (Lebanon), Amman (Jordan), Cairo, Alexandria, Ain Sokhna, (Egypt)) “Somatic depression and SSRI”

2010 Lecturer Solvay Pharmaceuticals Middle East Symposium (Zagreb)
“SSRI and Sigma receptors”

2010 Invited Speaker Servier CL2-20098-072 Study Investigators Meeting
(Amsterdam) “Efficacy of agomelatine in Obsessive-Compulsive Disorder.”

2010 Invited Speaker Eli Lilly NERI European Consultant Advisory Board Meeting (Madrid) “Subjective Experience and Basic Symptoms in Schizophrenic Patients”

2011 Course Director and Invited Speaker (Berlin, London, Athens, Rome, Munich and Paris) MAP – Managing Anxiety in Practice – Pfizer International “Anxiety in women: special considerations” Neurotrophic Factors in GAD: A Closer Look at Brain-derived Neurotrophic Factor and Artemin

2011 Invited Speaker, Thematic Conference (Istanbul) World Psychiatric
Association (WPA) “Gambling ADHD and mood stabilizers”

2011 Course Director, Chairman and Invited Speaker (Florence) European Certificate, International Master in Affective Neuroscience “Mood stabilizers in impulse control disorders”

2011 Member of the Board of Directors and Invited Speaker International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS) “Update on Agomelatin Preclinical and Clinical Data”

2011 Organizer, Course Director, Chairman and Invited Speaker (Florence) Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS “Recovery from OCD: a possible definition?”; “TMS in Depression and other clinical conditions”

2011 Chairman of the TEM meetings and Invited speaker (Paris) European College of Neuropsychopharmacology (ECNP) “Anxiety in the life span” “Disgust, passive-avoidance and treatment response in OCD”

2011 Invited Speaker (New York) Icare4Autism “Autism : Social Anxiety and executive dysfunction in adults”

2011 Invited Speaker (Milan) INNOPSY – International Forum Innovation in Psychiatry “Major Psychoses: Old concepts or new diagnostic clinical and therapeutic challenges”

2011 Invited Speaker (Florence) 3rd International Cardio Event – University of Florence “Emotional distress and Cardiovscular diseases: non Pharmacological interventions”

2011 Invited Speaker (Thessaloniki) 2nd Panhellenic Inter-scientific Congress of the Hellenic Association for the Study of Internet Addiction Disorder “Internet Addiction Disorder”

2011 Invited Speaker European Congress of Psychiatry (EPA) (Vienna)
“Generalized Anxiety Disorder”, “Low frequency rTMS in elderly”

2012 Course Director and Invited Speaker (London) MAP – Managing Anxiety in
Practice – Pfizer International “The GAD patient in focus”

2012 Chairman and Invited Speaker (Jerusalem) Icare4Autism “Bio-Medical
Research and Practice”

2012 Course Director, Chairman and Invited Speaker (Florence) European Certificate, International Master in Affective Neuroscience “Treatment of anxiety in bipolar disorder”

2012 Member of the Board of Directors and Invited Speaker International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS) “Treatment of OCD in bipolar disorder”

2012 Organizer, Course Director, Chairman and Invited Speaker (Florence) Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS ”Application of rTMS in the OCD spectrum”; “PANDAS and PANDAS like in Psychiatry”

2012 Chairman of the TEM meetings and Invited speaker (Vienna); European College of Neuropsychopharmacology (ECNP) (Vienna) Chair, Brain Storming Session “Time for Immuno Psychiatry?”

2012 Scientific Advisers Chair IFMAD International Forum on Mood and Anxiety Disorders (Barcellona) “Development in the treatments of Anxiety disorders”, “Is Hoarding a separate disorder?”

2013 Course Director and Invited Speaker (Berlin) MAP – Managing Anxiety in Practice – Pfizer International “Managing anxiety in practice: GAD now and beyond”

2013 Member of the Board of Directors and Invited Speaker Clinical TMS Society
Meeting : “TMS in mixed bipolar episode”

2013 Member of the Editorial Board and Invited Speaker CNS Spectrum Meeting
“The Emotional Endophenotype in Schizophrenia”

2013 Invited Speaker (Brescia) Brixia International Meeting – University of Brescia, Italy “Pathological gambling: new diagnostic boundaries and treatment options”

2013 Chairman of the TEM meetings and Invited speaker European College of Neuropsychopharmacology (ECNP)(Barcellona) “The role of anxiety in impulsive and compulsive disorders”

2013 Course Director, Chairman and Invited Speaker (Florence) European Certificate, International Master in Affective Neuroscience “ ADHD in bipolar disorder: Assessment and treatment ”

2013 Member of the Board of Directors and Invited Speaker International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS) “TMS for OCD: where are the targets? ”

2013 Organizer, Course Director, Chairman and Invited Speaker (Florence) Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS “ADHD adulto e disturbo bipolare”

2013 Invited Speaker (Kuala Lumpur) International Society of Addiction Medicine (ISAM) Conference “Internet Addiction: NO Substance Addiction?”

2013 Chairman, Co-Chairman, Invited Speaker (Milano) World Congress on ADHD Chair: “How to do best medication in adult ADHD?”; Co-Chair: “Update on treatment of ADHD across the lifespan”

2014 Member of the Editorial Board and Invited Speaker CNS Spectrum Meeting “rTMS as an add-on therapeutic tool in treatment refractory obsessive compulsive disorder”

2014 Member of the Board of Directors and Invited Speaker Clinical TMS Society Meeting “Low frequency bilateral rTMS in resistant OCD subjects: does the effect last?”

2014 Invited Speaker (Madrid) World Psychiatric Association (WPA) “Repetitive behavior disorders as a target for focal treatment”

2014 Chairman and Invited Speaker (Online meeting) Eli Lilly ADHD in Adult: Raise the Awareness of a Disease Still Unknown and Not Recognized “TMS for ASD and OCD”

2014 Chairman of the TEM meetings and Invited speaker European College of
Neuropsychopharmacology (ECNP) (Berlin) “Adult separation anxiety

disorder: boundaries causes and potential treatments”; “Is a paradigm shift in
Psychiatry long overdue?”

2014 Course Director, Chairman and Invited Speaker (Florence) European Certificate, International Master in Affective Neuroscience “Obsession and compulsion: an R-Do.C approach ”

2014 Chairman and Invited Speaker, International Forum on Mood and Anxiety Disorders (IFMAD) (Vienna) “Pharmacologic treatment of Obsessive- compulsive comorbidity”; “How to treat anxiety with comorbidity”

2014 Member of the Board of Directors and Invited Speaker International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS) “Neuromodulation: deep TMS and rTMS”

2014 Organizer, Course Director, Chairman and Invited Speaker (Florence) Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS “Curare le comorbidità”; “Neuromodulazione per i disturbi resistenti”

2015 Invited Speaker (Brescia) Brixia International Meeting – University of Brescia, Italy “Pluses and minuses of DSM-5 in depression and Anxiety disorders”; “Neurobiology of addictive behaviors”

2015 Member of the Editorial Board and Invited Speaker CNS Spectrum Meeting
“The clinician as a translational scientist “

2015 Member of the Board of Directors and Invited Speaker Clinical TMS Society Meeting “OCD with theta burst stimulation (TBS) of the pre-supplementary motor area (pre-SMA).”

2015 Scientific Advisory Board and Chairman of the TEM meeting and Invited speaker European College of Neuropsychopharmacology (ECNP) (Amsterdam) “Separation anxiety in adults”

2015 Invited Speaker (Milan) EXPO 2015 Symposium “Il Futuro della Salute Mentale” (Future of the Mental Health) “The Obsessive Compulsive Patient”

2015 Course Director, Chairman and Invited Speaker (Florence) European Certificate, International Master in Affective Neuroscience “Separation anxiety in ADHD”

2015 Chairman and Invited Speaker, International Forum on Mood and Anxiety Disorders (IFMAD) (Prague) “Pluses and minuses of DSM-5 in depression and anxiety disorders”

2015 Member of the Board of Directors and Invited Speaker International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS) “Multicenter rTMS trial”

2016 Invited Speaker (Brescia) Brixia International Meeting – University of Brescia, Italy “Neuromodulation of compulsive disorder: Experience and perspectives”; “Behavioral addiction: decision making and executive function disorder”

2016 Member of the Editorial Board and Invited Speaker CNS Spectrum Meeting
“Executive functions and OCD”

2016 Member of the Board of Directors and Invited Speaker Clinical TMS Society
Meeting “TMS for autism spectrum disorders”

2016 Scientific Advisory Board, Chairman of the ECNP Targeted Expert Meetings (TEM) meeting and Invited speaker European College of Neuropsychopharmacology (ECNP)(Vienna) “Future perspectives for treatment of anxiety disorders”

2016 Chair of Symposium on “New neural treatment targets in compulsive disorders” (Atlanta, GA) American Psychiatric Association (APA) “Repetitive behavior disorders as a target for focal treatment: TMS for ASD and OCD”

2016 Expert in Psychiatry, Chair and Invited Speaker (Bangkok) 4th ACNS – Asian Clinical Neuroscieces Summit Speaker “What is an integrated approach, and how does it help patients to achieve functional recovery? Expert Session: “Treatment of bipolar disorder patient with comorbid metabolic disorder”; Speaker “Targeting neuroinflammation in psychiatry: a prelude to optimal treatment?”; Speaker: “Reframing women’s mental helath: what are we missing?”

2016 Course Director, Chairman and Invited Speaker (Florence) European Certificate, International Master in Affective Neuroscience “Fear, Obsession and Trauma”

2016 Chairman and Invited Speaker, International Forum on Mood and Anxiety
Disorders (IFMAD) (Rome) “How should we treat resistant OCD?”

2016 Member of the Board of Directors and Invited Speaker International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS) “Pre- SMA target for TMS in OCD”

2016 Stand Alone Web Cast Lecturer (Online World-wide) Pfizer CNS World-wide
Web Cast Series “Neuro-inflammation and Mental Disorders”

2016 II Executive Committee Meeting (Madrid) European College of Neuropharmacology (ECNP) “Future perspectives for the treatment of anxiety disorders”

Grand Rounds

2012 University of Sydney, Brain and Mind Institute, Sydney, Australia “Social
Anxiety in Autism Spectrum Disorders: a new target for new treatments?”

2013 Albert Einstein College of Medicine of Yeshiva University, New York, USA
“Psychoses and Anxiety”

2016 Center for Neuropsychopharmacology, Centre for Restorative Neuroscience, Division of Brain Sciences, Faculty of Medicine, Imperial College, London, UK “Investigating and Treating Compulsivity with neuromodulation”

International Advisor-Researcher for The Development of Drugs

January 2000 – January 2001 SOLVAY INTERNATIONAL for FLUVOXAMINE

Janyary 2001 – January 2013 PFIZER for PREGABALIN SR

January 2006 – January 2010 TRANSCEPT PHARMACEUTICAL for ONDANSETRON January 2007 – January 2008 GSK for BUPROPION SR
January 2007 – January 2008 JAZZ PHARMACEUTICAL for FLUVOXAMINE International Advisor-Researcher for the Development of Technology
January 2008 – January 2009 BRAINSWAY for Neuromodulation technology

Paid Consultancy Agreements

2012 Chadbourne &Parke LLP, London, UK

2012 ALKS-5461 MDD Advisory Board, Alkermes Plc, Dublin, Ireland

2012 ProPhase, LLC, New York, USA

2013 CHILTERN International, Milan, Italy

2016 LEK Consulting, Boston, MA, USA

COMMUNITY SERVICE

Sept. 2000 Technical and Scientific Medical Consultant for the Italian Ministry of
University and Scientific Research and Technology

Jan. 2013 Technical Consultant for the Compagnia Carabinieri (Italian Armed Military
Police Force) in a criminal proceeding

July 2016 Technical Consultant for the Compagnia Carabinieri (Italian Armed Military
Police Force) in an internal proceeding

Iscriviti alla nostra Newsletter e seguici sui social network

Facebook
Twitter
YouTube

Pubblicazioni

è in uscita Firenze Neuroscienze, click sulla copertina per scaricarlo

Acquista su Amazon

Clicca per donare !

Tweet

Utilizzando il sito, accetti l'utilizzo dei cookie da parte nostra. maggiori informazioni

Questo sito utilizza i cookie per fornire la migliore esperienza di navigazione possibile. Sono presenti tre tipi di cookie: COOKIE c.d. TECNICI - si tratta di cookie utilizzati per permettere il corretto funzionamento e la corretta navigazione sul sito dell' Istituto di Neuroscienze. I cookie tecnici vengono ad esempio utilizzati per la funzionalità di login dell'utente. Sono erogati dai server dell' Istituto ma possono essere erogati anche da server di terzae parti come per esempio alcuni social network presenti nella pagine del sito. COOKIE c.d. ANALITICI - si tratta di cookie utilizzati al fine di analizzare i percorsi di navigazione, la provenienza ed il successivo indirizzo in uscita dei visitatori. Servono sostanzialmente per analisi statistiche e per l'individuazione di errori nel sito. I dati sono raccolti in modo anonimo. Sono erogati dal server dell' Istituto di Neuroscienza o da terze parti. COOKIE c.d. di PROFILAZIONE - questi cookie invece sono cookie che consentono di memorizzare sul computer del visitatore alcuno informazioni che possono essere poi reperite da terze parti. Servono per esempio per erogare pubblicità mirate in base al tipo di pagine e/o di domini visitati. L'accettazione dei cookie erogati durante la visita di www.istitutodineuroscienze.it comporta anche l'accettazione dei cookie di profilazione. Continuando a utilizzare questo sito senza modificare le impostazioni dei cookie o clicchi su "Accetta" permetti al loro utilizzo.

Chiudi